TP E 3037 305

Form PTO P149 U.S.Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

	T	1							U.S. PATENT	DOCUMENTS		- ₁	,		
*Exam. Init.	No.	Document No.							Date	Name	Class	Subclass	Filing Date		
	A	5	9	2	2	9	2	7	July 13, 1999	Bujard et al					
	В	5	9	1	7	1	2	2	June 29, 1999	Byrne					
	С	5	9	1	2	4	1	1	June 15, 1999	Bujard et al					
		-	ļ												
				-	<u> </u>	<u> </u>	+								
		1						F	OREIGN PATI	ENT DOCUMENT			1		
		Document No.									Class	SubClass	Trans Yes	slator No	
												3.00.200	1.00	T	
			1										 		
			-											1	
	I	<u> </u>								<u> </u>			<u> </u>	1	
		Τ	T		THE	CR DO	<u> CUN</u>	AEN'	rs (including A	uthor, Title Date, Pertin	ent Pages, Etc.)		 -		
	G		Vitale-Cross et al. (2004) "Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis" Cancer Res 64(15):8804-8807												
	F		Wang et al. (2004) "Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent color tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil" Cancel Res 64(18):6666-6672												
	E		Chin et al. (2000) "Flipping the oncogene switch: illumination of tumour maintenance and regression" Trends Genet 16(4): 147-150												
	D	T								as in tumour maintena	ance" Nature 40	00(6743) 4	68-47	2	